NEJM Journal Watch, Pediatrics & Adolescent medicine 12/2018
Fingolimod Pediatric Multiple Sclerosis Treatment
Approximately 3-5% of multiple sclerosis cases can occur in children before the age of 18.
Fingolimod (INN, Gilenya, Novartis) is a sphingosine 1-phosphate receptor modulator.
The results of treating pediatric multiple sclerosis with fingolimod are said to be more effective than those treated with interferon beta-1a.